Founders

Yehuda Zisapel

Founder and President

Yehuda ZisapelYehuda Zisapel holds an M.Sc. degree in Electronic Engineering from the Haifa Technion (Israel), an MBA from Tel-Aviv University
(Israel), and Doctor Honoris Causa from the Technion (Israel). He is the founder and director of the RAD Group, a holding that comprises 22 high-tech companies in computer communication technologies, six of which are publicly held and traded on the NASDAQ, and the chairman of Rad-Ramot Biomedical incubator. He has served as President of Neurim Pharmaceuticals since it commenced active operations in 1992.

Nava Zisapel

Founder and Chief Scientific Officer

Nava ZisapelNava Zisapel holds a B.Sc. in Chemistry, an M. Sc. in Biochemistry, and a Ph.D. in Biochemistry from Tel-Aviv University (Israel). She
is a full professor at Tel-Aviv University with a specialization in Neuro-biochemistry and the incumbent of the Michael Gluck Chair in Neuropharmacology and ALS Research. Nava Zisapel has authored with her students and collaborator scientists over 160 original research publications in peer-reviewed journals.

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
  • Partners

    Partners